LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

MannKind Corp

Затворен

СекторЗдравеопазване

4.59 2

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.5

Максимум

4.61

Ключови измерители

By Trading Economics

Приходи

-12M

668K

Продажби

-1.8M

77M

P/E

Средно за сектора

35.455

35.724

Марж на печалбата

0.873

Служители

403

EBITDA

-17M

9.7M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+105.45% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

5.2M

1.2B

Предишно отваряне

2.59

Предишно затваряне

4.59

Настроения в новините

By Acuity

15%

85%

22 / 372 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

MannKind Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.08.2025 г., 18:43 ч. UTC

Значими двигатели на пазара

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29.08.2025 г., 15:07 ч. UTC

Придобивния, сливания и поглъщания

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

29.08.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

29.08.2025 г., 20:24 ч. UTC

Печалби

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29.08.2025 г., 20:17 ч. UTC

Печалби

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29.08.2025 г., 19:18 ч. UTC

Пазарно говорене

Oil Futures End Week With Modest Gains -- Market Talk

29.08.2025 г., 18:59 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29.08.2025 г., 18:36 ч. UTC

Печалби

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29.08.2025 г., 18:26 ч. UTC

Печалби

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29.08.2025 г., 17:48 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29.08.2025 г., 17:10 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29.08.2025 г., 16:57 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29.08.2025 г., 16:30 ч. UTC

Придобивния, сливания и поглъщания

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29.08.2025 г., 16:28 ч. UTC

Придобивния, сливания и поглъщания

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29.08.2025 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29.08.2025 г., 16:26 ч. UTC

Придобивния, сливания и поглъщания

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29.08.2025 г., 16:25 ч. UTC

Придобивния, сливания и поглъщания

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29.08.2025 г., 16:24 ч. UTC

Придобивния, сливания и поглъщания

BBVA Adjusts Offer for Banco de Sabadell

29.08.2025 г., 16:23 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29.08.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

29.08.2025 г., 16:06 ч. UTC

Пазарно говорене

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29.08.2025 г., 15:12 ч. UTC

Пазарно говорене
Печалби

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29.08.2025 г., 15:09 ч. UTC

Печалби

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29.08.2025 г., 15:01 ч. UTC

Пазарно говорене

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29.08.2025 г., 14:49 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29.08.2025 г., 14:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

29.08.2025 г., 14:49 ч. UTC

Пазарно говорене

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29.08.2025 г., 14:48 ч. UTC

Печалби

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29.08.2025 г., 14:43 ч. UTC

Пазарно говорене

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

29.08.2025 г., 14:38 ч. UTC

Пазарно говорене

With Canada's Economy Soft, Central Bank Easing Looks Likely -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MannKind Corp Прогноза

Ценова цел

By TipRanks

105.45% нагоре

12-месечна прогноза

Среден 9.43 USD  105.45%

Висок 12 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за MannKind Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

7

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

4.079 / 4.323Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

22 / 372 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.